The Uromigos

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

膀胱がんの最新の話題〜周術期薬物療法とADC〜

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.

The RCC panel at Uromigos Live 2024 discusses and debates this topic.